| __timestamp | Blueprint Medicines Corporation | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 675200000 |
| Thursday, January 1, 2015 | 14456000 | 771800000 |
| Friday, January 1, 2016 | 19218000 | 1205500000 |
| Sunday, January 1, 2017 | 27986000 | 1146500000 |
| Monday, January 1, 2018 | 47928000 | 1125800000 |
| Tuesday, January 1, 2019 | 96388000 | 1166100000 |
| Wednesday, January 1, 2020 | 157743000 | 1175500000 |
| Friday, January 1, 2021 | 195293000 | 1111400000 |
| Saturday, January 1, 2022 | 237374000 | 1210100000 |
| Sunday, January 1, 2023 | 295141000 | 1274600000 |
Cracking the code
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Blueprint Medicines Corporation and Perrigo Company plc, two industry players, showcase contrasting strategies over the past decade. From 2014 to 2023, Blueprint Medicines saw a staggering 3,640% increase in SG&A expenses, starting from a modest $7.89 million to nearly $295 million. In contrast, Perrigo's SG&A costs grew by 89%, from $675 million to $1.27 billion.
Blueprint's rapid expansion reflects its aggressive growth strategy, while Perrigo's steadier increase suggests a focus on maintaining operational efficiency. Despite Blueprint's smaller scale, its SG&A expenses have grown at a much faster rate, indicating a potential area for cost optimization. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
SG&A Efficiency Analysis: Comparing Amgen Inc. and Perrigo Company plc
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Perrigo Company plc
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Vericel Corporation